Ascendis Pharma (ASND) announced that the FDA has accepted for review its supplemental biologics license application, or sBLA, in adult growth hormone deficiency, or GHD, for TransCon hGH. The FDA set ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback